Core Insights - Nuvation Bio Inc. reported a quarterly loss of $0.16 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.07 per share a year ago [1] - The company generated revenues of $3.08 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 23.36%, while revenues were zero a year ago [2] - Nuvation Bio's shares have declined approximately 21.4% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] Earnings Outlook - The earnings outlook for Nuvation Bio is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.18 on revenues of $2.5 million, and for the current fiscal year at -$0.69 on revenues of $15 million [7] - The company's earnings outlook will significantly depend on management's commentary during the earnings call [2] Industry Context - The Medical - Biomedical and Genetics industry, to which Nuvation Bio belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Nuvation Bio's stock performance [5]

Financial Performance - Smith Micro Software, Inc. reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, representing an earnings surprise of -45.45% [1] - The company posted revenues of $4.62 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 3.73%, and down from $5.8 million year-over-year [2] - Over the last four quarters, the company has only surpassed consensus EPS estimates once and has not beaten consensus revenue estimates [2] Stock Performance - Smith Micro Software shares have declined approximately 29.5% since the beginning of the year, compared to a decline of -4.7% for the S&P 500 [3] - The current status of estimate revisions is mixed, leading to a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $5.5 million, and for the current fiscal year, it is -$0.22 on revenues of $24.9 million [7] - The outlook for the industry, specifically the Computer - Software sector, is currently in the top 30% of Zacks industries, which may positively influence stock performance [8]

Company Performance - Schrodinger, Inc. reported a quarterly loss of $0.82 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.71, and compared to a loss of $0.76 per share a year ago, indicating a negative earnings surprise of -15.49% [1] - The company posted revenues of $59.55 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 6.81%, and showing significant growth from year-ago revenues of $36.6 million [2] - Over the last four quarters, Schrodinger has surpassed consensus revenue estimates three times, but has only exceeded EPS estimates once [2] Stock Outlook - Schrodinger shares have increased approximately 22.1% since the beginning of the year, contrasting with a -4.7% decline in the S&P 500 [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.76 for the coming quarter and -$2.47 for the current fiscal year [4][7] - The estimate revisions trend for Schrodinger is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical Info Systems industry, to which Schrodinger belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Scientific, Inc. (CORZ) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced a loss of $0.01, delivering a surprise of 90%.Over the last four quarters, the company has s ...

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28.30%. A quarter ago, it was expected that this specialty drug company would post earnings of $0.52 per share when it actually produced earnings of $0.70, delivering a surprise of 34.62%.Over the last four ...

Company Performance - Myomo, Inc. reported a quarterly loss of $0.08 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.10 per share a year ago [1] - The company posted revenues of $9.83 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 6.29%, compared to revenues of $3.75 million in the same quarter last year [2] - Over the last four quarters, Myomo has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2][3] Stock Outlook - Myomo shares have declined approximately 25.9% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $10.35 million, and for the current fiscal year, it is -$0.07 on revenues of $50.95 million [7] Industry Context - The Medical - Products industry, to which Myomo belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Myomo's stock performance [5][6]

分组1 - ElectroCore, Inc. reported a quarterly loss of $0.47 per share, better than the Zacks Consensus Estimate of a loss of $0.56, and an improvement from a loss of $0.53 per share a year ago, resulting in an earnings surprise of 16.07% [1] - The company posted revenues of $6.72 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.12%, but showing an increase from $5.44 million in the same quarter last year [2] - ElectroCore shares have declined approximately 57% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $7.62 million, and for the current fiscal year, it is -$1.36 on revenues of $31.44 million [7] - The Zacks Industry Rank for Medical - Drugs is in the top 26% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]

Core Viewpoint - Central Garden (CENT) reported quarterly earnings of $1.04 per share, exceeding the Zacks Consensus Estimate of $0.94 per share, and showing an increase from $0.99 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was 10.64%, with a significant prior quarter surprise of 800% when the company reported earnings of $0.21 per share against an expected loss of $0.03 [2] - Revenue for the quarter was $833.54 million, which fell short of the Zacks Consensus Estimate by 4.76% and decreased from $900.09 million year-over-year [3] - Over the last four quarters, the company has surpassed consensus EPS estimates four times but has only topped revenue estimates once [3] Stock Performance and Outlook - Central Garden shares have declined approximately 11% since the beginning of the year, compared to a 4.7% decline in the S&P 500 [4] - The company's earnings outlook is mixed, with current consensus EPS estimates of $1.32 for the upcoming quarter and $2.37 for the current fiscal year, alongside expected revenues of $1.01 billion and $3.23 billion respectively [8] Industry Context - The Consumer Products - Discretionary industry, to which Central Garden belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [9] - The performance of Central Garden's stock may be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [9]

Core Viewpoint - Groupon reported quarterly earnings of $0.18 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.20 per share, marking an earnings surprise of 190% [1] - The company generated revenues of $117.19 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.46%, although this represents a decline from $123.08 million year-over-year [2] Group 1: Earnings Performance - Groupon's earnings of $0.18 per share compare favorably to earnings of $0.06 per share a year ago, indicating growth [1] - The company has surpassed consensus EPS estimates two times over the last four quarters [2] Group 2: Revenue Insights - The reported revenue of $117.19 million exceeded the consensus estimate, but is lower than the previous year's revenue of $123.08 million [2] - Groupon has topped consensus revenue estimates three times in the last four quarters [2] Group 3: Stock Performance and Outlook - Groupon shares have increased by approximately 39.3% since the beginning of the year, contrasting with a -4.7% decline in the S&P 500 [3] - The company's future stock performance will largely depend on management's commentary during the earnings call [3][4] Group 4: Earnings Estimates and Industry Context - Current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $119.22 million, and -$0.25 on revenues of $497.1 million for the current fiscal year [7] - The Internet - Commerce industry is currently ranked in the top 31% of Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Helmerich & Payne (HP) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.86 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -96.92%. A quarter ago, it was expected that this oil and gas well-drilling contractor would post earnings of $0.69 per share when it actually produced earnings of $0.71, delivering a surprise of 2.90%.Over the las ...